Design Therapeutics, Inc. (DSGN) Stock Forecast
DSGN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $21.71 average of analyst targets
- Upside to target
- +110.6% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.38
- 52-week range
- $5.53 – $15.94
DSGN analyst ratings
8 analystsNumber of analysts at each rating.
DSGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DSGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.39 | −$0.30 | −$0.30 | −15.4% | 8 |
| Current fiscal year (2026) | −$1.35 | −$1.63 | −$1.23 | −$1.22 | −10.4% | 8 |
| Next fiscal year (2027) | −$1.62 | −$2.04 | −$1.17 | −$1.35 | −20.1% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DSGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
DSGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DSGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.35 | −$0.35 | −$0.35 | −$0.35 | −3.4% | 2 up · 1 down |
| Current fiscal year (2026) | −$1.36 | −$1.36 | −$1.36 | −$1.35 | −$1.35 | −0.9% | 3 up · 0 down |
| Next fiscal year (2027) | −$1.64 | −$1.59 | −$1.59 | −$1.62 | −$1.62 | −1.0% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DSGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DSGN beat in 10 of 12.
What analysts expect from DSGN
8 analysts cover Design Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.71, 110.6% above the latest close of $10.31. Analysts expect earnings of −$1.35 per share for 2026, −10.4% from a year earlier. For 2027 the average estimate is −$1.62 per share. Design Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: DSGN income statement, DSGN key metrics, DSGN chart. See the DSGN stock overview for the latest quote and news.
DSGN forecast FAQ
What is Design Therapeutics's price target?
The average analyst price target for Design Therapeutics is $21.71, 110.6% above the latest close of $10.31.
Is Design Therapeutics a buy, hold or sell?
Of 8 analysts covering Design Therapeutics, 6 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Design Therapeutics's EPS forecast?
Analysts forecast −$1.35 per share for 2026 (range −$1.63 to −$1.23); for 2027 the estimate is −$1.62.
When does Design Therapeutics report earnings?
Design Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.38.
Does Design Therapeutics usually beat earnings estimates?
Design Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.